References
- National Institute for Occupational Safety and Health: “Preventing occupational Exposure to Antineoplastic and Other Hazardous Drugs in Healthcare Settings.” Publ No. 2004-165. Cincinnati, OH: Department of Health and Human Services (US), Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health (2004). Available at http://www.cdc.gov/niosh/docs/2004-165/pdfs/2004-165.pdf (accessed February 25, 2017).
- National Institute for Occupational Safety and Health: “NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016.” Cincinnati, OH: Department of Health and Human Services (US), Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health (2015). Available at http://www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf (accessed February 25, 2017).
- Connor, T.H., C.C. Lawson, M. Polovich, and M.A. McDiarmid: Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings. J. Occup. Environ. Med. 56(9):901–910 (2014).
- United States Pharmacopeia: “<800>Hazardous Drugs—Handling in Healthcare Settings.” Available at http://www.usp.org/sites/default/files/usp_pdf/EN/m7808_pre-post.pdf (accessed February 25, 2017).
- National Institute for Occupational Safety and Health: “Occupational Exposure to Antineoplastic Agents and Other Hazardous Drugs.” Available at http://www.cdc.gov/niosh/topics/antineoplastic/sampling.html (accessed February 25, 2017).
- Occupational Safety and Health Administration: “Controlling Occupational Exposure to Hazardous Drugs.” Available at https://www.osha.gov/SLTC/hazardousdrugs/controlling_occex_hazardousdrugs.html (accessed February 25, 2017).
- Canadian Society of Hospital Pharmacists: “CSHP Compounding: Gidelines for Pharmacies.” (2014). Available at http://www.cshp.ca/productsServices/officialPublications/guidelines_2014_e.asp (accessed February 25, 2017).
- Association Paritaire pour la Santé et la Sécurité du Travail du Secteur Affaires Sociales: “Prevention Guide, Safe Handling of Hazardous Drugs.” (2008). Available at http://www.asstsas.qc.ca/sites/default/files/publications/documents/Guides_Broch_Depl/GP65A_hazardous_drugs.pdf (accessed February 25, 2017).
- Ordre des Pharmaciens du Québec: “Norme 2014.02 - Préparation de Produits Stériles Dangereux en Pharmacie.” Montréal (QC). (2014) Available at www.opq.org/fr-CA/publications/normes-de-pratique-et-lignes-directrices/ (accessed February 25, 2017).
- Bussières, J.F., C. Tanguay, K. Touzin, É. Langlois, and M. Lefebvre: Environmental contamination with hazardous drugs in Quebec hospitals. Can. J. Hosp. Pharm. 65(6):428–435 (2012).
- Merger, D., C. Tanguay, E. Langlois, M. Lefebvre, and J.F. Bussières: Multicenter study of environmental contamination with antineoplastic drugs in 33 Canadian hospitals. Int. Arch. Occup. Environ. Health 87(3):307–313 (2014).
- Berruyer, M., C. Tanguay, N.J. Caron, M. Lefebvre, and J.F. Bussières: Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: a 2013 follow-up study. J. Occup. Environ. Hyg. 12(2):87–94 (2015).
- Janes, A., C. Tanguay, N.J. Caron, and J.F. Bussières: Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Can. J. Hosp. Pharm. 68(4):279–289 (2015).
- Poupeau, C., C. Tanguay, N.J. Caron, and J.F. Bussières: “Multicenter study of environmental contamination with antineoplastic drugs in 47 Canadian hospitals.” Poster presented at Professional Practice Conference - Canadian Society of Hospital Pharmacists, Toronto, ON, Canada, February 1–3, 2016.
- Larson, R.R., M.B. Khazaeli, and H.K. Dillon: Monitoring method for surface contamination caused by selected antineoplastic agents. Am. J. Health Syst. Pharm. 59(3):270–277 (2002).
- Official Journal of the European Union: “Commission directive 2009/90/CE of 31 July 2009. Article 5: Calculation of mean values.” (2009) Available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:201:0036:0038:EN:PDF (accessed February 25, 2017).
- Hornung, R.W., and L.D. Reed: Estimation of average concentration in the presence of nondetectable values. Appl. Occup. Environ. Hyg. 5(1):46–51 (1990).
- Simon, N., M. Vasseur, M. Pinturaud, et al.: Effectiveness of a closed-system transfer device in reducing surface contamination in a new antineoplastic drug-compounding unit: A prospective, controlled, parallel study. PLoS One 8;11(7):e0159052 (2016).
- Guillemette, A., H. Langlois, M. Voisine, et al.: Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device. J. Oncol. Pharm. Pract. 20(6):426–432 (2014).
- Sessink, P.J., J. Trahan, and J.W. Coyne: Reduction in surface contamination with cyclophosphamide in 30 US hospital pharmacies following implementation of a closed-system drug transfer device. Hosp. Pharm. 48(3):204–212 (2013).
- Connor, T.H., M.D. Zock, and A.H. Snow: Surface wipe sampling for antineoplastic (chemotherapy) and other hazardous drug residue in healthcare settings: Methodology and recommendations. J. Occup. Environ. Hyg. 13(9):658–667 (2016).
![Supercharge Your Next Research Paper: Research and write your next paper with Jenni AI.]({"type":"image" , "src" : "/sda/112440/MPU-Jenni-AI-ECONOMICS.png"})